特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
534921

重症筋無力症(MG):疫学的予測

Myasthenia Gravis - Epidemiology Forecast to 2028

出版日: | 発行: DelveInsight Business Research LLP | ページ情報: 英文 50 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.64円
重症筋無力症(MG):疫学的予測
出版日: 2019年01月01日
発行: DelveInsight Business Research LLP
ページ情報: 英文 50 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)における重症筋無力症(MG)の総有病数は2016年に12万9,267人と見積もられています。

当レポートでは、重症筋無力症(MG)について調査し、疾病の概要、患者背景、主要7カ国における重症筋無力症(MG)の有病数・診断数の予測(今後10年間分)、市場の成長機会などを包括的にまとめています。

目次

第1章 重要洞察

第2章 重症筋無力症:市場概要

第3章 市場シェア・重症筋無力症の分布(最新値)

第4章 市場シェア・重症筋無力症の分布(予測値)

第5章 疾患概要:重症筋無力症

  • イントロダクション
  • 重症筋無力症の種類
  • 重症筋無力症:MGFA分類
  • 病因
  • 重症筋無力症の遺伝的概要
  • リスク因子
  • 兆候と症状
  • 重症筋無力症の病態生理
  • 重症筋無力症併存疾患
  • 診断

第6章 疫学と患者人口

  • 主な所見
  • 人口と予測パラメーター
  • 主要7カ国の総患者人口
  • 重症筋無力症の疫学:国別
    • 米国
    • 前提と根拠
    • 重症筋無力症の有病数
    • 重症筋無力症の有病数:性別
    • 重症筋無力症の診断数
    • 重症筋無力症の診断数:重症度別
    • 重症筋無力症の診断数:自己抗体別
  • ドイツ
    • 前提と根拠
    • 重症筋無力症の有病数
    • 重症筋無力症の有病数:性別
    • 重症筋無力症の診断数
    • 重症筋無力症の診断数:重症度別
    • 重症筋無力症の診断数:自己抗体別
  • フランス
    • 前提と根拠
    • 重症筋無力症の有病数
    • 重症筋無力症の有病数:性別
    • 重症筋無力症の診断数
    • 重症筋無力症の診断数:重症度別
    • 重症筋無力症の診断数:自己抗体別
  • イタリア
    • 前提と根拠
    • 重症筋無力症の有病数
    • 重症筋無力症の有病数:性別
    • 重症筋無力症の診断数
    • 重症筋無力症の診断数:重症度別
    • 重症筋無力症の診断数:自己抗体別
  • スペイン
    • 前提と根拠
    • 重症筋無力症の有病数
    • 重症筋無力症の有病数:性別
    • 重症筋無力症の診断数
    • 重症筋無力症の診断数:重症度別
    • 重症筋無力症の診断数:自己抗体別
  • 日本
    • 前提と根拠
    • 重症筋無力症の有病数
    • 重症筋無力症の有病数:性別
    • 重症筋無力症の診断数
    • 重症筋無力症の診断数:重症度別
    • 重症筋無力症の診断数:自己抗体別

第7章 市場の成長要因

第8章 市場の阻害要因

第9章 付録

第10章 報告方法

第11章 DelveInsightのサービス内容

第12章 免責事項

第13章 DelveInsightについて

図表

List of Tables

  • Table 1: Total Prevalent/Incident Cases of the Myasthenia Gravis in 7MM
  • Table 2: Total Prevalent/Incident Cases of the Myasthenia Gravis in 7MM by Countries
  • Table 3: Prevalent/Incident Cases of the Myasthenia Gravis in United States (2016-2028)
  • Table 4: Sub-Type Specific cases of the Myasthenia Gravis in United States (2016-2028)*
  • Table 5: Sex- Specific Cases of the Myasthenia Gravis in United States (2016-2028)*
  • Table 6: Diagnosed Cases of the Myasthenia Gravis in United States (2016-2028)
  • Table 7: Prevalent/Incident Cases of the Myasthenia Gravis in Germany (2016-2028)
  • Table 8: Sub-Type Specific cases of the Myasthenia Gravis in Germany (2016-2028) *
  • Table 9: Sex- Specific Cases of the Myasthenia Gravis in Germany (2016-2028) *
  • Table 10: Diagnosed Cases of the Myasthenia Gravis in Germany (2016-2028)
  • Table 11: Prevalent/Incident Cases of the Myasthenia Gravis in France (2016-2028)
  • Table 12: Sub-Type Specific cases of the Myasthenia Gravis in France (2016-2028) *
  • Table 13: Sex- Specific Cases of the Myasthenia Gravis in France (2016-2028) *
  • Table 14: Diagnosed Cases of the Myasthenia Gravis in France (2016-2028)
  • Table 15: Prevalent/Incident Cases of the Myasthenia Gravis in Italy (2016-2028)
  • Table 16: Sub-Type Specific cases of the Myasthenia Gravis in Italy (2016-2028) *
  • Table 17: Sex- Specific Cases of the Myasthenia Gravis in Italy (2016-2028) *
  • Table 18: Diagnosed Cases of the Myasthenia Gravis in Italy (2016-2028)
  • Table 19: Prevalent/Incident Cases of the Myasthenia Gravis in Spain (2016-2028)
  • Table 20: Sub-Type Specific cases of the Myasthenia Gravis in Spain (2016-2028) *
  • Table 21: Sex- Specific Cases of the Myasthenia Gravis in Spain (2016-2028) *
  • Table 22: Diagnosed Cases of the Myasthenia Gravis in Spain (2016-2028)
  • Table 23: Prevalent/Incident Cases of the Myasthenia Gravis in UK (2016-2028)
  • Table 24: Sub-Type Specific cases of the Myasthenia Gravis in UK (2016-2028) *
  • Table 25: Sex- Specific Cases of the Myasthenia Gravis in UK (2016-2028) *
  • Table 26: Diagnosed Cases of the Myasthenia Gravis in UK (2016-2028)
  • Table 27: Prevalent/Incident Cases of the Myasthenia Gravis in Japan (2016-2028)
  • Table 28: Sub-Type Specific cases of the Myasthenia Gravis in Japan (2016-2028) *
  • Table 29: Sex- Specific Cases of the Myasthenia Gravis in Japan (2016-2028) *
  • Table 30: Diagnosed Cases of the Myasthenia Gravis in Japan (2016-2028)

List of Figures

  • Figure 1: Total Prevalent/Incident Cases of the Myasthenia Gravis in 7MM
  • Figure 2: Total Prevalent/Incident Cases of the Myasthenia Gravis in 7MM by Countries
  • Figure 3: Prevalent/Incident Cases of the Myasthenia Gravis in United States (2016-2028)
  • Figure 4: Sub-Type Specific cases of the Myasthenia Gravis in United States (2016-2028)*
  • Figure 5: Sex- Specific Cases of the Myasthenia Gravis in United States (2016-2028)*
  • Figure 6: Diagnosed Cases of the Myasthenia Gravis in United States (2016-2028)
  • Figure 7: Prevalent/Incident Cases of the Myasthenia Gravis in Germany (2016-2028)
  • Figure 8: Sub-Type Specific cases of the Myasthenia Gravis in Germany (2016-2028) *
  • Figure 9: Sex- Specific Cases of the Myasthenia Gravis in Germany (2016-2028) *
  • Figure 10: Diagnosed Cases of the Myasthenia Gravis in Germany (2016-2028)
  • Figure 11: Prevalent/Incident Cases of the Myasthenia Gravis in France (2016-2028)
  • Figure 12: Sub-Type Specific cases of the Myasthenia Gravis in France (2016-2028) *
  • Figure 13: Sex- Specific Cases of the Myasthenia Gravis in France (2016-2028) *
  • Figure 14: Diagnosed Cases of the Myasthenia Gravis in France (2016-2028)
  • Figure 15: Prevalent/Incident Cases of the Myasthenia Gravis in Italy (2016-2028)
  • Figure 16: Sub-Type Specific cases of the Myasthenia Gravis in Italy (2016-2028) *
  • Figure 17: Sex- Specific Cases of the Myasthenia Gravis in Italy (2016-2028) *
  • Figure 18: Diagnosed Cases of the Myasthenia Gravis in Italy (2016-2028)
  • Figure 19: Prevalent/Incident Cases of the Myasthenia Gravis in Spain (2016-2028)
  • Figure 20: Sub-Type Specific cases of the Myasthenia Gravis in Spain (2016-2028) *
  • Figure 21: Sex- Specific Cases of the Myasthenia Gravis in Spain (2016-2028) *
  • Figure 22: Diagnosed Cases of the Myasthenia Gravis in Spain (2016-2028)
  • Figure 23: Prevalent/Incident Cases of the Myasthenia Gravis in UK (2016-2028)
  • Figure 24: Sub-Type Specific cases of the Myasthenia Gravis in UK (2016-2028) *
  • Figure 25: Sex- Specific Cases of the Myasthenia Gravis in UK (2016-2028) *
  • Figure 26: Diagnosed Cases of the Myasthenia Gravis in UK (2016-2028)
  • Figure 27: Prevalent/Incident Cases of the Myasthenia Gravis in Japan (2016-2028)
  • Figure 28: Sub-Type Specific cases of the Myasthenia Gravis in Japan (2016-2028) *
  • Figure 29: Sex- Specific Cases of the Myasthenia Gravis in Japan (2016-2028) *
  • Figure 30: Diagnosed Cases of the Myasthenia Gravis in Japan (2016-2028)
目次
Product Code: DIEI0145

DelveInsight's "Myasthenia Gravis - Epidemiology Forecast, 2028" report provides a comprehensive analysis of the Myasthenia Gravis epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

Markets Covered

  • United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2016-2028

Myasthenia Gravis Epidemiology

The epidemiology section covers the historical, current as well as forecasted epidemiology for Myasthenia Gravis in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders' views are also taken into account to provide a deep understanding of the Myasthenia Gravis outlook. It also includes the explanation of changing trends of epidemiology outlining the Myasthenia Gravis scenario.

Myasthenia Gravis Epidemiology Segmentation

The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Myasthenia Gravis thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope

  • The report covers detailed overview of Myasthenia Gravis explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
  • The Myasthenia Gravis Report assesses the disease risk and burden and highlights the unmet needs
  • It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Total Cases in Myasthenia Gravis

Key assessments

  • Patient Segmentation in Myasthenia Gravis
  • Myasthenia Gravis Risk & Burden
  • Factors driving growth in a specific Myasthenia Gravis patient population

Table of Contents

1. Report Introduction

2. Myasthenia Gravis Epidemiology Overview at a Glance

  • 2.1. Patient Share Distribution of Myasthenia Gravis in 2016
  • 2.2. Patient Share Distribution of Myasthenia Gravis in 2028

3. Disease Background and Overview: Myasthenia Gravis

  • 3.1. Introduction
  • 3.2. Symptoms
  • 3.3. Etiology
  • 3.4. Risk Factors
  • 3.5. Pathophysiology
  • 3.6. Diagnosis
  • 3.7. Treatment

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Total Prevalent/ Incident Patient Population of Myasthenia Gravis in 7MM
  • 4.3. Total Prevalent/ Incident Patient Population of Myasthenia Gravis in 7MM - By Countries

5. Epidemiology of Myasthenia Gravis by Countries

  • 5.1. United States
    • 5.1.1. Assumptions and Rationale
    • 5.1.2. Prevalent/Incident Cases of the Myasthenia Gravis
    • 5.1.3. Sub-Type Specific cases of the Myasthenia Gravis *
    • 5.1.4. Sex- Specific Cases of the Myasthenia Gravis *
    • 5.1.5. Diagnosed Cases of the Myasthenia Gravis
  • 5.2. EU5
  • 5.3. Assumptions and Rationale
  • 5.4. Germany
    • 5.4.1. Assumptions and Rationale
    • 5.4.2. Prevalent/Incident Cases of the Myasthenia Gravis
    • 5.4.3. Sub-Type Specific cases of the Myasthenia Gravis *
    • 5.4.4. Sex- Specific Cases of the Myasthenia Gravis *
    • 5.4.5. Diagnosed Cases of the Myasthenia Gravis
  • 5.5. France
    • 5.5.1. Assumptions and Rationale
    • 5.5.2. Prevalent/Incident Cases of the Myasthenia Gravis
    • 5.5.3. Sub-Type Specific cases of the Myasthenia Gravis *
    • 5.5.4. Sex- Specific Cases of the Myasthenia Gravis *
    • 5.5.5. Diagnosed Cases of the Myasthenia Gravis
  • 5.6. Italy
    • 5.6.1. Assumptions and Rationale
    • 5.6.2. Prevalent/Incident Cases of the Myasthenia Gravis
    • 5.6.3. Sub-Type Specific cases of the Myasthenia Gravis *
    • 5.6.4. Sex- Specific Cases of the Myasthenia Gravis *
    • 5.6.5. Diagnosed Cases of the Myasthenia Gravis
  • 5.7. Spain
    • 5.7.1. Assumptions and Rationale
    • 5.7.2. Prevalent/Incident Cases of the Myasthenia Gravis
    • 5.7.3. Sub-Type Specific cases of the Myasthenia Gravis *
    • 5.7.4. Sex- Specific Cases of the Myasthenia Gravis *
    • 5.7.5. Diagnosed Cases of the Myasthenia Gravis
  • 5.8. United Kingdom
    • 5.8.1. Assumptions and Rationale
    • 5.8.2. Prevalent/Incident Cases of the Myasthenia Gravis
    • 5.8.3. Sub-Type Specific cases of the Myasthenia Gravis *
    • 5.8.4. Sex- Specific Cases of the Myasthenia Gravis *
    • 5.8.5. Diagnosed Cases of the Myasthenia Gravis
  • 5.9. Japan
    • 5.9.1. Assumptions and Rationale
    • 5.9.2. Prevalent/Incident Cases of the Myasthenia Gravis
    • 5.9.3. Sub-Type Specific cases of the Myasthenia Gravis *
    • 5.9.4. Sex- Specific Cases of the Myasthenia Gravis *
    • 5.9.5. Diagnosed Cases of the Myasthenia Gravis

6. Unmet Needs of the Myasthenia Gravis

7. Appendix

8. Report Methodology

  • 8.1. Sources

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

Indication Specific

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.